Second-generation drug-eluting stents

Second-generation drug-eluting stents

Release date: 2009-02-03


Led by Academician Gao Runlin, Academician of the Chinese Academy of Engineering and Chairman of the Chinese Cardiovascular Society, Firebird2 (Firebird 2), the second-generation cobalt-chromium alloy drug-eluting stent developed by MicroPort Medical Devices Co., Ltd., was launched in January and has been widely used. In the clinic.

According to reports, compared with the first generation of stainless steel drug stents, Firebird 2 has a thinner stent wire, thinner metal thickness, stronger support force and better flexibility, which can be applied to various complex lesions. Reduce the incidence of postoperative vascular restenosis by 15% to 20%, and perform nuclear magnetic resonance examination.

After clinical observation, the incidence of adverse events in the two years after the firebird 2 was 1.5%. No related stent thrombosis events were observed during the two-year follow-up. Shanghai Medical Device Industry Association

Bulk of Rabies Vaccine For Human Use(semi-Finished Products)

1. The standard for internal control is higher than national standard. The Rabies Vaccine has high potency and has good immunogenicity.

2. The vaccine shows good safety with low ratio in adverse reaction. The product is suitable for large scope vaccination in exposure area.

Rabies Vaccine

Final Bulk

Bulk Of Rabies Vaccine,Mild Bulk Of Rabies Vaccine,Stable Rabies Vaccine

Changchun BCHT Biotechnology Co. , https://www.ccbcht.com